The Mexico cancer biomarkers market was valued at USD 335.95 Million in 2025 and is expected to grow at a CAGR of 7.40%, reaching USD 685.99 Million by 2035. The market growth is driven by the rising cancer prevalence, growing adoption of precision medicine, and increasing demand for early detection through biomarker-based diagnostics.
Base Year
Historical Period
Forecast Period
Mexico’s progress in molecular oncology and the integration of biomarkers into personalized therapies are set to strengthen the dominance of diagnostics in the market.
The 2023 UNAM-led study on breath analysis using mass spectrometry reflects Mexico’s focus on developing innovative, non-invasive biomarker detection methods.
The rising cancer burden, with 207,154 new cases reported in 2022, is driving greater reliance on biomarker-based diagnostics for early detection.
Compound Annual Growth Rate
7.4%
Value in USD Million
2026-2035
*this image is indicative*
The market is witnessing significant growth, driven by rising cancer prevalence and advancements in precision medicine. Increasing awareness, improved screening programs, and adoption of targeted therapies are key factors propelling this expansion. Breast cancer remains the most prominent segment, while research, diagnostics, and prognostics continue to gain traction. The market is also benefiting from innovations in molecular diagnostics and personalized treatment approaches, supporting early detection and better patient outcomes across various cancer types. The market is expected to grow at a CAGR of 7.40% during the forecast period of 2026-2035 and attain a market value of USD 685.99 Million by 2035.
Rising Adoption of Molecular Diagnostics and Personalized Cancer Therapies to Drive Market Growth
Increasing demand for early cancer detection and growing awareness of precision medicine are driving the expansion of cancer biomarker applications. For instance, a 2025 study published in the International Journal of Molecular Sciences highlighted Mexico’s advancements in molecular oncology, emphasizing the integration of biomarkers into diagnostics and personalized treatment strategies. This research demonstrates the country’s commitment to enhancing cancer care infrastructure, which is expected to accelerate adoption of biomarker-based solutions. Consequently, these developments are likely to significantly bolster market growth and innovation throughout the forecast period.
Major market trends include rising cancer prevalence and technological innovations.
Adoption of Non-Invasive Cancer Detection Techniques to Enhance Market Value
In August 2023, researchers at the National Autonomous University of Mexico (UNAM) initiated a study utilizing advanced mass spectrometry to analyze exhaled breath for cancer biomarkers. This approach aimed to identify volatile organic compounds indicative of early-stage cancers, offering a non-invasive diagnostic alternative. The integration of such innovative technologies is expected to drive market growth by enhancing early detection capabilities and reducing diagnostic costs, thereby influencing the cancer biomarkers market positively during the forecast period.
Rising Cancer Prevalence Driving Mexico Cancer Biomarkers Market Demand
The growing cancer burden in Mexico is fueling the expansion of the cancer biomarkers market. In 2022, approximately 207,154 new cancer cases were reported, with age-standardized rates of 140.9 per 100,000 persons. Prostate and breast cancers remain the most prevalent, with ASRs of 39.1 and 39.9 per 100,000, respectively. Cancer is also the fourth leading cause of premature mortality, accounting for 30% of deaths before age 75. This increasing prevalence emphasizes the urgent need for early detection and personalized biomarker-based diagnostics, driving market growth during the forecast period.
Diagnostics to Lead the Market Share by Application
Among application segments, diagnostics is expected to hold the largest share of the market. This dominance is supported by the rising cancer incidence and the growing emphasis on early detection to improve survival outcomes. In terms of revenue, Mexico accounted for 2% of the global cancer diagnostics market in the historical period, underscoring its rising position in this domain. With breast and prostate cancers among the most prevalent in the country, demand for biomarker-driven diagnostics is projected to accelerate, ensuring this segment maintains the largest market share.
The key features of the market report comprise funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Illumina, Inc., founded in 1998 and headquartered in San Diego, California, develops integrated systems for genetic analysis, including sequencing, genotyping, and proteomics. Notable products include NovaSeq, MiSeq, TruSight Oncology, and DRAGEN for cancer biomarker applications. Its platforms are widely used in diagnostics, research, and personalized medicine across academic and clinical settings.
Established in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd. is one of the world’s largest biotech companies and a leader in oncology care. Roche combines advanced diagnostics with targeted therapies, leveraging biomarker-based testing to guide personalized treatment approaches. Its portfolio includes companion diagnostics and innovative cancer drugs that transform patient outcomes. By focusing heavily on biomarker-driven oncology, Roche strengthens its position in precision medicine, ensuring broader clinical adoption and market relevance across global cancer care, including Mexico’s growing biomarker landscape.
Bio-Rad Laboratories, Inc., founded in 1952 and headquartered in Hercules, California, develops life science research and clinical diagnostic solutions. Its portfolio includes droplet digital PCR systems, immunoassays, and genomic analysis tools widely used for cancer biomarker applications. These technologies are essential for biomarker quantification and early cancer diagnostics. Bio-Rad reported strong results in its diagnostics unit, generating nearly USD 389 million in Q3 2024 revenue, driven by heightened demand for clinical testing solutions.
Qiagen N.V., founded in 1984 and headquartered in Venlo, Netherlands, with operational headquarters in Hilden, Germany, is a leading provider of molecular diagnostics and research tools. Its portfolio includes nucleic acid purification, PCR, and next-generation sequencing technologies supporting cancer biomarker detection. Qiagen focuses on advancing companion diagnostics and liquid biopsy solutions for oncology applications.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Hologic, Inc., Quest Diagnostics Clinical Laboratories, Inc., and Charles River Laboratories.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Cancer Type
Market Breakup by Application
Market Breakup by Profiling Technology
Market Breakup by End User
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Cancer Type |
|
| Breakup by Application |
|
| Breakup by Profiling Technology |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share